Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

IL-17 promoted metastasis of non-small-cell lung cancer cells.

Li Q, Han Y, Fei G, Guo Z, Ren T, Liu Z.

Immunol Lett. 2012 Dec 17;148(2):144-50. doi: 10.1016/j.imlet.2012.10.011. Epub 2012 Oct 23.

PMID:
23089548
2.

Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer.

Yamaji H, Iizasa T, Koh E, Suzuki M, Otsuji M, Chang H, Motohashi S, Yokoi S, Hiroshima K, Tagawa M, Nakayama T, Fujisawa T.

Cancer Immunol Immunother. 2004 Sep;53(9):786-92. Epub 2004 Jun 4.

PMID:
15185009
3.

Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: Enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells.

Chen X, Xie Q, Cheng X, Diao X, Cheng Y, Liu J, Xie W, Chen Z, Zhu B.

Cancer Sci. 2010 Nov;101(11):2384-90. doi: 10.1111/j.1349-7006.2010.01684.x. Epub 2010 Sep 1.

4.

Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.

Zhang W, Chen Y, Wei H, Zheng C, Sun R, Zhang J, Tian Z.

Clin Cancer Res. 2008 Oct 15;14(20):6432-9. doi: 10.1158/1078-0432.CCR-07-4401.

5.

Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.

Dalwadi H, Krysan K, Heuze-Vourc'h N, Dohadwala M, Elashoff D, Sharma S, Cacalano N, Lichtenstein A, Dubinett S.

Clin Cancer Res. 2005 Nov 1;11(21):7674-82.

6.

IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells.

Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng KS, Huang CY.

Am J Physiol Lung Cell Mol Physiol. 2005 Sep;289(3):L446-53. Epub 2005 May 13.

7.

IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.

Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H.

J Immunol. 2005 Nov 1;175(9):6177-89.

8.

Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor.

Li J, Zhang L, Zhang J, Wei Y, Li K, Huang L, Zhang S, Gao B, Wang X, Lin P.

Carcinogenesis. 2013 Mar;34(3):658-66. doi: 10.1093/carcin/bgs384. Epub 2012 Dec 17.

PMID:
23250909
9.

Reciprocal activation between IL-6/STAT3 and NOX4/Akt signalings promotes proliferation and survival of non-small cell lung cancer cells.

Li J, Lan T, Zhang C, Zeng C, Hou J, Yang Z, Zhang M, Liu J, Liu B.

Oncotarget. 2015 Jan 20;6(2):1031-48.

10.

Antiproliferative effect of human interleukin-4 in human cancer cell lines: studies on the mechanism.

Topp MS, Papadimitriou CA, Eitelbach F, Oelmann E, Koehler B, Oberberg D, Von Marschall Z, Reufi B, Stein H, Thiel E, et al.

Leuk Lymphoma. 1995 Oct;19(3-4):319-28.

PMID:
8535226
11.

Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells.

Yin ZJ, Jin FG, Liu TG, Fu EQ, Xie YH, Sun RL.

J Surg Res. 2011 Dec;171(2):675-83. doi: 10.1016/j.jss.2010.03.053. Epub 2010 Apr 18.

PMID:
20605584
12.

Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression.

Kirshberg S, Izhar U, Amir G, Demma J, Vernea F, Beider K, Shlomai Z, Wald H, Zamir G, Shapira OM, Peled A, Wald O.

PLoS One. 2011;6(9):e24856. doi: 10.1371/journal.pone.0024856. Epub 2011 Sep 15.

13.

Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer.

Pan B, Shen J, Cao J, Zhou Y, Shang L, Jin S, Cao S, Che D, Liu F, Yu Y.

Sci Rep. 2015 Nov 3;5:16053. doi: 10.1038/srep16053.

14.

Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells.

Su L, Zhang J, Xu H, Wang Y, Chu Y, Liu R, Xiong S.

Clin Cancer Res. 2005 Dec 1;11(23):8273-80.

15.

STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma.

Tu B, Du L, Fan QM, Tang Z, Tang TT.

Cancer Lett. 2012 Dec 1;325(1):80-8. doi: 10.1016/j.canlet.2012.06.006. Epub 2012 Jun 26.

PMID:
22743617
16.

Up-regulation of interleukin-17 expression by human papillomavirus type 16 E6 in nonsmall cell lung cancer.

Chang YH, Yu CW, Lai LC, Tsao CH, Ho KT, Yang SC, Lee H, Cheng YW, Wu TC, Shiau MY.

Cancer. 2010 Oct 15;116(20):4800-9. doi: 10.1002/cncr.25224.

17.

Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells.

Zhu YM, Azahri NS, Yu DC, Woll PJ.

BMC Cancer. 2008 Jul 31;8:218. doi: 10.1186/1471-2407-8-218.

18.

The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation.

Kanou T, Oneyama C, Kawahara K, Okimura A, Ohta M, Ikeda N, Shintani Y, Okumura M, Okada M.

Mol Cancer Res. 2011 Jan;9(1):103-14. doi: 10.1158/1541-7786.MCR-10-0340. Epub 2010 Dec 14.

19.

Interleukin-22 promotes lung cancer cell proliferation and migration via the IL-22R1/STAT3 and IL-22R1/AKT signaling pathways.

Bi Y, Cao J, Jin S, Lv L, Qi L, Liu F, Geng J, Yu Y.

Mol Cell Biochem. 2016 Apr;415(1-2):1-11. doi: 10.1007/s11010-016-2663-8. Epub 2016 Mar 17.

PMID:
26983629
20.

RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.

Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang S, Wang W, Zhang J, Zhang Y.

Eur J Cancer. 2011 Oct;47(15):2353-63. doi: 10.1016/j.ejca.2011.05.006. Epub 2011 Jun 15.

PMID:
21680174

Supplemental Content

Support Center